Rescue of Tumor-Infiltrating Lymphocytes from Activation-Induced Cell Death Enhances the Antitumor CTL Response in CD5-Deficient Mice

The CD5 coreceptor is expressed on all T cells and on the B1a B cell subset. It is associated with TCR and BCR, and modulates intracellular signals initiated by both Ag receptor complexes. Human CD5 contributes to regulation of the antitumor immune response and susceptibility of specific CTL to activation-induced cell death (AICD) triggered by the tumor. In this study, we compared the T cell response to the B16F10 melanoma engrafted into CD5-deficient and wild-type C57BL/6 mice. Compared with wild-type mice, CD5 knockout animals displayed delayed tumor growth, associated with tumor infiltration by T cell populations exhibiting a more activated phenotype and enhanced antitumor effector functions. However, control of tumor progression in CD5−/− mice was transient due to increased AICD of CD8+ tumor-infiltrating T lymphocytes. Remarkably, in vivo protection of T cells from TCR-mediated apoptosis by an adenovirus engineered to produce soluble Fas resulted in a dramatic reduction in tumor growth. Our data suggest that recruitment of tumor-specific T cells in the tumor microenvironment occurs at early stages of cancer development and that tumor-mediated AICD of tumor-infiltrating T lymphocytes is most likely involved in tumor escape from the immune system.

[1]  S. Fiering,et al.  A Conserved Enhancer Element Differentially Regulates Developmental Expression of CD5 in B and T Cells , 2010, The Journal of Immunology.

[2]  Marion H. Brown,et al.  A Ligand for CD5 Is CD5 , 2010, The Journal of Immunology.

[3]  M. Nishimura,et al.  Inhibition of superoxide generation upon T-cell receptor engagement rescues Mart-1(27-35)-reactive T cells from activation-induced cell death. , 2009, Cancer research.

[4]  J. Yélamos,et al.  The CD5 ectodomain interacts with conserved fungal cell wall components and protects from zymosan-induced septic shock-like syndrome , 2009, Proceedings of the National Academy of Sciences.

[5]  D. Cohen,et al.  CD5 plays an inhibitory role in the suppressive function of murine CD4(+) CD25(+) T(reg) cells. , 2008, Immunology letters.

[6]  C. Richon,et al.  Human CD5 Protects Circulating Tumor Antigen-Specific CTL from Tumor-Mediated Activation-Induced Cell Death1 , 2007, The Journal of Immunology.

[7]  S. Barnum,et al.  CD5-CK2 Binding/Activation-Deficient Mice Are Resistant to Experimental Autoimmune Encephalomyelitis: Protection Is Associated with Diminished Populations of IL-17-Expressing T Cells in the Central Nervous System1 , 2006, The Journal of Immunology.

[8]  P. Opolon,et al.  Expression of non‐signaling membrane‐anchored death receptors protects murine livers in different models of hepatitis , 2006, Hepatology.

[9]  W. Tan,et al.  FASL –844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer , 2005, The Journal of experimental medicine.

[10]  S. Anderton,et al.  Fas‐mediated death and sensory adaptation limit the pathogenic potential of autoreactive T cells after strong antigenic stimulation , 2005, Journal of leukocyte biology.

[11]  Robert C. Rose,et al.  Local Radiation Therapy of B16 Melanoma Tumors Increases the Generation of Tumor Antigen-Specific Effector Cells That Traffic to the Tumor1 , 2005, The Journal of Immunology.

[12]  P. Opolon,et al.  In Situ Sensory Adaptation of Tumor-Infiltrating T Lymphocytes to Peptide-MHC Levels Elicits Strong Antitumor Reactivity1 , 2005, The Journal of Immunology.

[13]  S. Rosenberg,et al.  Survival, Persistence, and Progressive Differentiation of Adoptively Transferred Tumor-Reactive T Cells Associated with Tumor Regression , 2005, Journal of immunotherapy.

[14]  S. Rosenberg,et al.  Transfer Therapy Cancer Regression in Patients Receiving Cell Lymphocyte Clonotypes Correlates with Cutting Edge: Persistence of Transferred , 2022 .

[15]  K. Hiraoka,et al.  Enhanced Tumor-Specific Long-Term Immunity of Hemaggluttinating Virus of Japan-Mediated Dendritic Cell-Tumor Fused Cell Vaccination by Coadministration with CpG Oligodeoxynucleotides1 , 2004, The Journal of Immunology.

[16]  S. Barnum,et al.  Cutting Edge: Critical Role for CD5 in Experimental Autoimmune Encephalomyelitis: Inhibition of Engagement Reverses Disease in Mice1 , 2004, The Journal of Immunology.

[17]  M. Nussenzweig,et al.  Immunological unresponsiveness characterized by increased expression of CD5 on peripheral T cells induced by dendritic cells in vivo. , 2004, Immunity.

[18]  K. Hiraoka,et al.  Enhanced tumor-specific long-term immunity of hemagglutinating [correction of hemaggluttinating] virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides. , 2004, Journal of immunology.

[19]  D. Kioussis,et al.  Chronic Exposure to Low Levels of Antigen in the Periphery Causes Reversible Functional Impairment Correlating with Changes in CD5 Levels in Monoclonal CD8 T Cells , 2003, The Journal of Immunology.

[20]  A. Trautmann,et al.  CD5 Inhibits Signaling at the Immunological Synapse Without Impairing Its Formation 1 , 2003, The Journal of Immunology.

[21]  B. Stockinger,et al.  Involvement of Avidity for Major Histocompatibility Complex in Homeostasis of Naive and Memory T Cells , 2003, The Journal of experimental medicine.

[22]  F. Sánchez‐Madrid,et al.  The Accessory Molecules CD5 and CD6 Associate on the Membrane of Lymphoid T Cells* , 2003, The Journal of Biological Chemistry.

[23]  F. Mami-Chouaib,et al.  Tumor-Infiltrating CD4+ T Lymphocytes Express APO2 Ligand (APO2L)/TRAIL upon Specific Stimulation with Autologous Lung Carcinoma Cells: Role of IFN-α on APO2L/TRAIL Expression and -Mediated Cytotoxicity1 , 2002, The Journal of Immunology.

[24]  A. Singer,et al.  CD5‐mediated inhibition of TCR signaling during intrathymic selection and development does not require the CD5 extracellular domain , 2002, European journal of immunology.

[25]  Georges Bismuth,et al.  CD5-Negative Regulation of B Cell Receptor Signaling Pathways Originates from Tyrosine Residue Y429 Outside an Immunoreceptor Tyrosine-Based Inhibitory Motif1 , 2002, The Journal of Immunology.

[26]  R. Budd,et al.  Activation-induced cell death. , 2001, Current opinion in immunology.

[27]  C. Park,et al.  Fine Tuning of TCR Signaling by CD5 , 2001, The Journal of Immunology.

[28]  A. Tarakhovsky,et al.  Negative regulation of CD4 lineage development and responses by CD5. , 1999, Journal of immunology.

[29]  M. Bowen,et al.  Interaction of recombinant and natural soluble CD5 forms with an alternative cell surface ligand , 1999, European journal of immunology.

[30]  S. Rosenberg,et al.  Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition. , 1999, Journal of immunology.

[31]  R. Siegel,et al.  Mature T lymphocyte apoptosis--immune regulation in a dynamic and unpredictable antigenic environment. , 1999, Annual review of immunology.

[32]  A. Grinberg,et al.  CD5 Expression Is Developmentally Regulated By T Cell Receptor (TCR) Signals and TCR Avidity , 1998, The Journal of experimental medicine.

[33]  A. Aruffo,et al.  A role for CD5 in cognate interactions between T cells and B cells, and identification of a novel ligand for CD5. , 1998, International immunology.

[34]  I. Stamenkovic,et al.  Identification of a novel inducible cell-surface ligand of CD5 on activated lymphocytes , 1996, The Journal of experimental medicine.

[35]  K. Rajewsky,et al.  A role for CD5 in TCR-mediated signal transduction and thymocyte selection. , 1995, Science.

[36]  P. Fink,et al.  Positive selection of thymocytes. , 1995, Annual review of immunology.

[37]  K. Rajewsky,et al.  Lymphocyte populations and immune responses in CD5‐deficient mice , 1994, European journal of immunology.

[38]  M. Krieger,et al.  The SRCR superfamily: a family reminiscent of the Ig superfamily. , 1994, Trends in biochemical sciences.

[39]  A. Williams,et al.  Molecular associations between the T-lymphocyte antigen receptor complex and the surface antigens CD2, CD4, or CD8 and CD5. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[40]  H. Velde,et al.  The B-cell surface protein CD72/Lyb-2 is the ligand for CDS , 1991, Nature.

[41]  M. Freeman,et al.  Type I macrophage scavenger receptor contains α-helical and collagen-like coiled coils , 1990, Nature.

[42]  M. Freeman,et al.  Type I macrophage scavenger receptor contains alpha-helical and collagen-like coiled coils. , 1990, Nature.

[43]  J. Strominger,et al.  Isolation of complementary DNA clones encoding the human lymphocyte glycoprotein T1/Leu-1 , 1986, Nature.